( March 20, 2025, 18:45 GMT | Official Statement) -- MLex Summary: Pfizer, Sumitomo Pharma and Takeda Pharmaceuticals filed a patent infringement suit in the US District of Delaware against MSN Pharmaceuticals in opposition to MSN’s Abbreviated New Drug Application to sell a generic version of prostate cancer drug Orgovyx. The plaintiffs allege MSN’s generic version, relugolix, infringes two patents for the drug which expire in 2033 and 2037. The patents-in-suit are U.S. Patent Nos. 11,795,178 and 12,097,198.See complaint attached....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.